If a patient develops sexual adverse effects after one year of finasteride therapy, are these effects likely to resolve after stopping the medication?

Sexual Adverse Effects After 1 Year of Finasteride Use: Resolution Likelihood

Sexual adverse effects that develop after one year of finasteride use show mixed resolution patterns: while many resolve during continued treatment or after discontinuation, a subset of patients experience persistent dysfunction that may not fully resolve.

Key Evidence on Resolution Patterns

During Continued Treatment

The FDA label and clinical trial data provide the most authoritative guidance on this issue. In the PLESS trial, sexual adverse events that occurred during treatment resolved while continuing therapy in only 12% of finasteride patients compared to 19% of placebo patients 1. More importantly, the PCPT trial data showed that sexual dysfunction associated with finasteride decreased over time during continued treatment, though it remained statistically significant 2.

The PLESS study specifically demonstrated that new drug-related sexual adverse events occurred with increased incidence only during the first year of therapy 3. After year 1, the incidence of new sexual adverse events was identical between finasteride and placebo groups (7% in each group during years 2-4) 3.

After Discontinuation

The resolution picture after stopping finasteride is more concerning. Among men who discontinued due to sexual adverse events, only 50% experienced resolution after stopping finasteride (compared to 41% in placebo) 1, 3. This means approximately half of patients who develop sexual dysfunction severe enough to warrant discontinuation will continue to experience symptoms.

Critical FDA Warning

The FDA label explicitly warns about sexual dysfunction that continued after discontinuation of treatment, including erectile dysfunction, decreased libido, and ejaculation disorders 1. These persistent effects have been reported in postmarketing surveillance, though the independent role of finasteride in these events remains uncertain given that most affected men were older with comorbid conditions and concomitant medications 1.

Clinical Implications

What to Tell Patients

• If sexual side effects develop after 1 year of use:
  • Approximately 12% may resolve while continuing treatment
  • If discontinuation is chosen, roughly 50% will experience resolution
  • The other 50% may have persistent symptoms of uncertain duration

Common Pitfalls to Avoid

1. Do not assume all sexual dysfunction will resolve upon stopping the drug - the evidence clearly shows persistent dysfunction occurs in a substantial minority
2. Do not dismiss patient concerns about persistent symptoms - postmarketing data confirms cases of continued sexual dysfunction after discontinuation 1
3. Consider the timing carefully - sexual adverse events occurring after 1 year of treatment are less common than those in the first year, but when they do occur, resolution patterns are similar 3

Risk Context

The overall discontinuation rate due to sexual adverse events was only 4% for finasteride versus 2% for placebo 3, suggesting most patients either don't develop severe symptoms or find them tolerable. However, for those who do develop significant dysfunction, the 50% non-resolution rate after discontinuation represents a meaningful quality-of-life concern that must be discussed during informed consent.

The evidence does not support reassuring patients that sexual side effects developing after prolonged use are "likely to resolve" - the data suggests resolution is essentially a coin flip after discontinuation.